Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge

Sumitomo Pharma closed its books for FY2022 with an operating loss of 77 billion yen, battered by a 54.4-billion-yen impairment charge booked due to the forecast review of Kynmobi (apomorphine), a sluggish Parkinson’s therapy. According to its earnings reported on...read more